Introduction
============

The emergence of drug resistant bacteria represent a global threat to human health and is now a top priority of the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC) programs for the treatment of infectious diseases. Particularly, the emergence of drug resistance in *Escherichia coli* requires close attention since the rate of isolates resistant to the commonly used antibiotics is rising worldwide ([@ref-45]; [@ref-9]). The current therapeutic options are scarce to deal with these infections. Therefore, studies on new drugs and drug combinations as well as an improved understanding of the mechanism of action of these new drugs have become critical to fight the spread of multidrug resistant organisms.

In Gram-negative bacteria, besides the acquired resistance by the acquisition of external resistance determinants or mutations in genes that code for the drug targets, the intrinsic drug resistance also play an important role in the resistance towards antibiotics and biocides ([@ref-41]; [@ref-28]; [@ref-29]; [@ref-22]). This resistance occurs as a consequence of the (i) presence of an outer membrane that create a permeability barrier reducing the influx of antimicrobials, and (ii) overexpression of efflux pumps that help to reduce the intracellular level of antimicrobials and toxins ([@ref-22]; [@ref-28]).

The efflux pumps of the RND (resistant nodulation cell division) superfamily have been clearly associated with multidrug resistant phenotypes in Gram-negative pathogens ([@ref-22]). The substrates of the RND efflux pumps are different in their structure and physicochemical properties and include antibiotics, detergents, and biocides ([@ref-28]; [@ref-16]). The clinical implication of this substrate promiscuity is the development of multidrug resistance. The major RND efflux system of *E. coli* consists in a typical tripartite efflux pump, the AcrAB-TolC. This structure is composed by an integral membrane efflux transporter (AcrB), an outer membrane channel (TolC), and a periplasmic adapter protein (AcrA) ([@ref-8]). Upon entering in the cell, the compounds will interact with the substrate-binding pocket of AcrB, which will extrude the compounds via TolC using the energy produced by the proton motive force (PMF) ([@ref-23]). The AcrAB activity and overexpression have been associated with the resistance to fluoroquinolones, chloramphenicol, tetracycline, β-lactams, and β-lactamase inhibitors, among others, as well as biofilm formation and pathogenicity ([@ref-29]). Beside the AcrAB-TolC efflux pump, other *E. coli* efflux systems also play a role in the development of drug resistance ([@ref-41]; [@ref-24]). The overexpression of these efflux systems in response to the antibiotic stress is commonly the first step in the evolution of antibiotic resistance in the bacterial population, favoring the spontaneous appearance and stabilization of chromosomal mutations in the genes related with the antibiotic action. This biological phenomenon leads to the emergence of resistance to almost all classes of antibiotics available and require the urgent implementation of novel therapeutic strategies for the management of these infections.

The inhibition of the efflux activity may be of great potential once used in combination therapies by restoring or enhancing the activity of the currently used antimicrobials and preventing the emergence of drug resistance. Several compounds capable of inhibiting *E. coli* efflux pumps have been described ([@ref-17]; [@ref-39]; [@ref-2]; [@ref-27]; [@ref-37]; [@ref-46]; [@ref-3]; [@ref-47]) but, to date, none has reached the clinical development mainly due to their toxicity. Moreover, the putative mechanisms of action of the great majority of the efflux inhibitors currently in study remain largely unknown. The most known *E. coli* efflux inhibitors are the peptidomimetic phenyl-arginine- β-naphthylamide (PAβN) and the phenothiazine chlorpromazine (CPZ). PAβN is a potent inhibitor of *Pseudomonas aeruginosa* efflux pumps ([@ref-17]) and is a substrate competitor of the AcrAB efflux pump of *E. coli* ([@ref-40]). Recently, [@ref-21] showed that PAβN acts as an inhibitor of the AcrAB and AcrEF efflux systems at low concentrations, and as a membrane-destabilizing agent when used at higher concentrations. The phenothiazine CPZ presents efflux inhibitory activity against *E. coli* efflux systems ([@ref-39]). The phenothiazines mode of action involve the disruption of the calcium-calmodulin transport and signaling pathways ([@ref-34]; [@ref-31]), modifications at the level of the bacterial membrane and on nucleic acid stability ([@ref-31]; [@ref-36]), and inhibition of the type II NADH-ubiquinone dehydrogenase ([@ref-44]; [@ref-35]).

In recent studies, the 2-phenylquinoline derivative PQQ4R showed to be active as an efflux pump inhibitor of the Gram-positive *Staphylococcus aureus* ([@ref-33]; [@ref-32]) and non-tuberculous mycobacteria ([@ref-18]) but nothing is known about its mode of action. In this work, we aimed to unravel the mode of action of PQQ4R as efflux pump inhibitor, as in the search for new and effective efflux inhibitors is important to understand their inhibitory mechanism of action and to disclosure the presence of non-efflux related mechanisms ([@ref-38]). Because drug efflux is energy dependent, we hypothesize that the mode by which PQQ4R inhibits drug efflux involves the interference with the cell energetic state. We evaluated the activity of PQQ4R using three *E. coli* isogenic strains differing only in the level of expression of its major efflux pump system--- the AcrAB-TolC system - and compared its activity with that of the known *E. coli* efflux inhibitors PAβN and CPZ. We found that PQQ4R interferes with *E. coli* membrane integrity, therefore reducing the activity of *E. coli* efflux pumps. The understanding gathered on the molecular mechanism of action of the efflux inhibitor PQQ4R may aid in the development of less toxic and more potent efflux inhibitors against *E. coli* efflux pumps.

Materials & Methods
===================

Bacteria and growth conditions
------------------------------

The strains included in the study were the wild-type *E. coli* K-12 AG100 (*argE3 thi-1 rpsL xyl mtl*Δ (*gal-uvrB*)*supE44*); the AcrAB pump-deficient *E. coli* AG100A (Δ*acrAB*), and the AcrAB overexpressing *E. coli* AG100~tet~. The strain AG100A is a derivative of AG100 and has the AcrAB system inactivated due to an insertion of the transposon Tn*903* (Δ*acrAB*::Tn*903* Kan^r^) ([@ref-11]; [@ref-26]). AG100~tet~ is a derivative of AG100 obtained by continuous exposure to increasing concentrations of tetracycline (TET) ([@ref-39]). The strains were grown in Luria-Bertani (LB) broth at 37 °C with shaking. AG100A was grown in presence kanamycin (KAN) at 100 µg/ml to maintain the transposon and AG100~tet~ was grown in media supplemented with TET at 8 µg/ml to maintain the overexpression of efflux pumps.

Chemicals
---------

Ofloxacin (OFX), oxacillin (OXA), KAN, TET, ethidium bromide (EtBr), CPZ, PAβN, carbonyl cyanide-*m*-chlorophenylhydrazone (CCCP), glucose, and phosphate-buffered saline (PBS) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The 2-phenylquinoline PQQ4R was synthesized as previously described ([@ref-32]).

Antibacterial activity evaluation
---------------------------------

The minimum inhibitory concentrations (MICs) were determined using the broth microdilution method according to the CLSI guidelines ([@ref-6]). The synergistic activity between the efflux inhibitors, antibiotics and EtBr was evaluated by checkerboard assays as previously described ([@ref-30]; [@ref-7]). Two-fold serial dilutions of the compounds were made to achieve the following concentrations: 320 µM--40 µM. The MICs were determined as the lowest concentration at which no visible growth was observed after 18 h of incubation at 37 °C. The assays were performed in triplicate and the MIC value was given as result of at least two concordant values.

Evaluation of efflux activity by real-time fluorometry
------------------------------------------------------

The effect of the inhibitors on EtBr accumulation and efflux was assessed by fluorometry as previously described ([@ref-40]; [@ref-42]). The strains were grown until an OD~600nm~ of 0.6 at 37 °C with shaking. After, the cells were collected by centrifugation at 16,060× g for 3 min, washed in PBS and centrifuged again.

For the accumulation assays, the OD~600nm~ of the cell suspension was adjusted to 0.6 by adding PBS, allowing the assay to run with a final OD of 0.3. To determine the EtBr concentration at which influx and efflux are in equilibrium, the accumulation assays were performed in presence of increasing concentrations of the dye. The assays were prepared to a final volume of 100 µl containing 50 µl of the cellular suspension (final OD~600nm~ of 0.3) plus 50 µl of EtBr solutions to final concentrations ranging from 0.0625 to 5 µg/ml. The effect of the inhibitors on the accumulation of EtBr was evaluated in a final volume of 100 µl containing 50 µl of the cellular suspension (final OD~600nm~ of 0.3) and 50 µl of a solution containing EtBr at the equilibrium concentration and the compounds to a final concentration of 80 µM for AG100 and AG100~tet~, and 20 µM for AG100A. The molar concentrations used represent $\documentclass[12pt]{minimal}
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}{}$ \frac{1}{4} $\end{document}$ or less of the MIC determined for each compound against each strain (see [Table 1](#table-1){ref-type="table"}) in order to guarantee that the real-time efflux inhibitory effects measured were not due to any antimicrobial effect of the compound. The assays were conducted in a Rotor-Gene 3000 (Corbett Research, Sydney, Australia) at 37 °C, and the fluorescence acquired at 530/585 nm at the end of every 60 s, for 30 min. The activity of the compounds on the accumulation of EtBr was evaluated by the relative final fluorescence (RFF) index according to the formula: RFF = (RF~treated~-- RF~untreated~)/RF~untreated~. In this formulae the RF~treated~ corresponds to the fluorescence at the last time point of the EtBr accumulation curve (minute 30) in the presence of an inhibitor and the RF~untreated~ corresponds to the fluorescence at the last time point of the EtBr accumulation curve of the control tube ([@ref-20]). The experiments were done in triplicate and the RFF values are presented as the average of three independent assays (±SD).
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###### Minimum inhibitory concentration (MIC) determination of the antibiotics, EtBr and efflux inhibitors against the *E. coli* strains.

![](peerj-05-3168-g009)

                          MIC for the *E. coli* strains                                      
  ----------------------- ------------------------------- ------- -------- ------- --------- ---------
  **Antibiotics**                                                                            
  OFX                     0.25                            --      0.0313   --      1         --
  TET                     2                               --      0.5      --      64        --
  OXA                     512                             --      2        --      \>2,048   --
  **Efflux inhibitors**                                                                      
  PQQ4R                   256                             653.9   32       81.7    \>256     \>653.9
  CPZ                     120                             337.8   60       168.9   280       788
  PAβN                    \>200                           \>385   50       96.3    \>200     \>385
  **Efflux substrate**                                                                       
  EtBr                    200                             --      3.125    --      512       --

**Notes.**

*E. coli* AG100---wild-type.

*E. coli* AG100A---AG100 with the AcrAB-TolC efflux pump inactivated.

*E. coli* AG100~tet~---AG100 with efflux pump overexpression.

CPZchlorpromazineEtBrethidium bromideOFXofloxacinOXAoxacillinPAβNphe-arg- β-naphthylamideTETtetracycline

For the efflux assays, the strains were exposed to conditions that promote maximum accumulation of EtBr, i.e., EtBr at the equilibrium concentration for each strain, no glucose, presence of the efflux inhibitors, and incubation at room temperature for 1 h ([@ref-42]). The OD~600nm~ of the cell suspension was adjusted to 0.3 and incubated with EtBr under the conditions described above. Aliquots of 50 µl of the cells were transferred to tubes containing 50 µl of each efflux inhibitor at 80 µM (AG100 and AG100~tet~) or 20 µM (AG100A) without EtBr. Control tubes with only cells and cells with and without 0.4% glucose were included. The fluorescence was measured in a Rotor-Gene 3000 and the data was acquired every 30 s for 30 min at 37 °C. The efflux activity was quantified by comparing the fluorescence data obtained under conditions that promote efflux (presence of glucose and absence of efflux inhibitor) with the data from the control in which the bacteria are under conditions of no efflux (presence of an inhibitor and no energy source). The relative fluorescence corresponds to the ratio of the fluorescence that remains per unit of time, relatively to the EtBr-loaded cells ([@ref-40]; [@ref-42]).

Time-kill kinetics
------------------

The determination of the killing activity of PQQ4R was analysed by time-kill assays as previously described ([@ref-30]) with slight modifications. Briefly, AG100 was grown until OD~600nm~ of 0.6 at 37 °C with shaking. Exponential bacterial cultures were diluted in Mueller-Hinton Broth (MHB) to a cell density of 1 × 10^5^ cells/ml and 500 µl added to test tubes containing MHB and PQQ4R at the desired concentration. The compound was added to each tube to achieve the final concentrations of 8× to 0.5× the MIC. A drug-free control was included in the assay to monitor the normal growth of the strain. Cultures were sampled for CFU determination after 0, 1, 2, 3, 4, 5, 6, and 24 h of incubation at 37 °C with shaking. For CFU determination, 10-fold serial dilutions were made in a saline solution and 20 µl of each solution was placed onto the surface of a Mueller--Hinton agar plate. The colonies were counted after the incubation of the plates at 37 °C for 24 h. The limit of detection of the assay was 17 CFU/ml. Each assay was repeated at least twice.

Membrane potential assay
------------------------

The effect of PQQ4R on the membrane potential was measured using the BacLight Bacterial Membrane Potential Kit (Molecular Probes, Life Technologies) according to the manufacturer's instructions. CPZ and PAβN were tested for comparison. AG100 was grown at 37 °C with shaking until reach OD~600nm~ 0.6. After this, the cells were washed in PBS and diluted to 1 × 10^7^ CFU/ml with PBS. PQQ4R was added to the cell suspension at concentrations from 640 to 80 µM. The samples were transferred into black flat bottom 96-well plates, 30 µM of DiOC~2~ (3) was added to the mixture, and the plates were incubated during 30 min in the dark. The fluorescence was measured using a Synergy HT multi-mode microplate reader (BioTek Instruments Inc, Vermont, USA) with the filters 485/20 (excitation) and 528/20 (emission) for green and 590/35 (emission) for red. CCCP was used as positive control at 156 µM (half MIC), since it eradicates the proton gradient, eliminating the membrane potential. The red to green ratio was determined and normalized against the emission from the DiOC~2~ (3) blank well and the results are presented as the percentage of depolarized membranes (±SD) compared with the drug-free control.

Membrane permeability assay
---------------------------

The evaluation of the membrane integrity was done using the Live/Dead BacLight Bacterial Viability Kit (Molecular Probes, Life Technologies) according to the manufacturer's instructions. AG100 was grown at 37 °C with shaking until OD~600nm~ of 0.6. Samples of 500 µl were incubated with PQQ4R at concentrations from 640 to 80 µM during 1 h at room temperature. The cells were collected by centrifugation at 16,060× g for 10 min, the supernatant was discarded and the pellet resuspended in the same volume of a saline solution. Then, 100 µl of the cell suspension were transferred into black flat bottom 96-well plates and the dyes propidium iodide and SYTO 9 (ratio 1:1) were added to each well to stain the cells. The plate was incubated during 15 min at room temperature in the dark. The fluorescence was measured using a Synergy HT multi-mode microplate reader with the filters 485/20 (excitation) and 528/20 (emission) for green and 590/35 (emission) for red. The green to red ratio was determined and the results are presented as the percentage of intact membranes (±SD) compared with the control (no treatment). CPZ and PAβN were included for comparison.

Intracellular ATP levels determination
--------------------------------------

The ATP levels were measured using the ATP Determination Kit (Invitrogen, Life Technologies, Paisley, UK) according to the manufacturer's instructions. AG100 was grown until OD~600nm~ of 0.6 at 37 °C with shaking. Exponential bacterial cultures were diluted in MHB to a cell density of 1 × 10^5^ cells/ml and 500 µl added to test tubes containing MHB and PQQ4R at half MIC and at the MIC. A drug-free control was included in the assay to monitor the normal growth of the strain. Aliquots of bacteria were collected at 0, 1, 2, 3, 4, 5, 6, and 24 h of incubation at 37 °C, with shaking, inactivated by heating and immediately deep frozen. The cell lysates were transferred into white flat bottom 96-well plates and the ATP content measured using a Synergy HT multi-mode microplate reader and expressed as relative luminescence units. CPZ and PAβN were included for comparison.

Cytotoxicity against human monocyte-derived macrophages
-------------------------------------------------------

The blood was collected from healthy donors and the peripheral blood mononuclear cells were isolated by Ficoll-Paque Plus (GE Healthcare, Freiburg, Germany) density gradient centrifugation as previously described ([@ref-19]). Briefly, monocytes were differentiated into macrophages during 7 days in RPMI-1640 medium with 10% fetal calf serum (FCS), 1% GlutaMAX™, 1 mM sodium pyruvate, 10 mM HEPES at pH 7.4, 100 IU/ml penicillin and 100 µg/ml streptomycin (Gibco, Life Technologies), and 20 ng/ml M-CSF (Immunotools, Friesoythe, Germany) and incubated at 37 °C in a 5% CO~2~ atmosphere. Fresh medium was added at day 4 post isolation. The effect of the compounds on human monocyte-derived macrophages was evaluated using the AlamarBlue method (Molecular Probes, Life Technologies) ([@ref-25]), and by measuring the release of the lactate dehydrogenase (LDH) into the culture supernatants using the Pierce LDH Cytotoxicity Assay (ThermoFisher Scientific, Waltham, MA, USA) ([@ref-5]) according to the manufacturer's instructions. Briefly, 5 × 10^4^ cells were seeded in 96-well microplates treated with the compounds, and incubated at 37 °C with 5% CO~2~. After 72 h of treatment, the cell viability was assessed. For the AlamarBlue method, the dye was added to each well to a final concentration of 10% and incubated overnight at 37 °C and 5% CO~2~. The fluorescence was measured with a 540/35 excitation filter and a 590/20 emission filter in a Synergy HT multi-mode microplate reader. The release of LDH from damaged cells into culture supernatants, as an indicator of cytotoxicity, was measured in serum-free medium. Here the amount of enzyme activity correlates to the number of damaged cells. The specific lysis was calculated as follows: (treated cells---spontaneous LDH release)/ (maximum LDH release---spontaneous LDH release) ×100. The inhibitory concentration IC~50~ (50%) value was calculated using GraphPad Prism V5.01 software (La Jolla, USA). The IC~10~ (10%) and IC~90~ (90%) were calculated using the GraphPad program "ECanything" available online ([@ref-12]).

Statistical analysis
--------------------

Statistical analysis was carried out using the Student's *t*-test. A *P* value \<0.05 was considered statistically significant and highly significant when ^∗∗^*P* \< 0.01 and ^∗∗∗^*P* \< 0.001 (two-tailed tested).

Results
=======

Synergistic activity of PQQ4R in combination with antimicrobials
----------------------------------------------------------------

The MICs of the antibiotics, which are substrates of the AcrAB efflux pump, the efflux substrate EtBr, PQQ4R, and for comparison, PAβN and CPZ, known *E. coli* efflux inhibitors, were determined for the wild-type AG100, the pump deficient AG100A, and the pump-overexpressing AG100~tet~ ([Table 1](#table-1){ref-type="table"}). AG100A is more susceptible to the selected antibiotics and EtBr than the wild-type, due to the absence of a functional AcrAB, reconfirming that these antibiotics are substrates of this pump ([@ref-28]; [@ref-39]). The susceptibility data also showed that neither PQQ4R nor PAβN and CPZ had, by themselves, antimicrobial activity against the *E. coli* strains. Moreover, PQQ4R MIC decreased 8-fold against AG100A once compared with the wild-type parental strain, indicating that, PQQ4R might be a substrate of the AcrAB system. Similar results were observed for PAβN.

To assess whether PQQ4R potentiated the activity of the tested antibiotics against *E. coli*, the MICs of OFX, OXA, and TET were determined in the presence of PQQ4R. PAβN and CPZ were tested at the same concentrations for a direct comparison of their activities ([Table 2](#table-2){ref-type="table"}). Against the wild-type strain, PQQ4R, at concentrations ranging from 40 to 160 µM, produced a 2-fold reduction in OFX and TET MICs, while a 2- or 4-fold reduction on the MICs of EtBr at 80 and 160 µM, respectively, were observed. On the contrary, no effect was observed for OXA. Interestingly, PQQ4R at concentrations of 80 and 160 µM, significantly increased the antibacterial activity of OFX and TET in the AcrAB-overexpressing strain AG100~tet,~ (AcrAB overexpressed 6--10 times compared with the isogenic wild-type strain---[@ref-39]; [@ref-41]) causing a 4-fold decrease in their MICs, with a marginal effect on the MIC of EtBr. In accordance with the increased susceptibility detected above, the pump deficient AG100A did not grow in presence of PQQ4R at concentrations above 40 µM and this concentration had no effect on the MIC of the antibiotics. However, this concentration caused a ≈8-fold reduction in the EtBr MIC for AG100A, confirming that other efflux pumps, that extrude EtBr (AcrEF, among others), are active in this strain ([@ref-39]; [@ref-41]).

10.7717/peerj.3168/table-2

###### Synergistic effect of PQQ4R, PA*β*N, and CPZ on the MIC values of antibiotics and EtBr against the *E. coli* strains.

![](peerj-05-3168-g010)

                **MIC (*μ*g/ml)**                                                                                                                                                                                               
  ------------- ----------------------- ----------------------- ----------------------- ----------------------- --------- ---------- --------- ----------- ----- ----------- --------- ----------- ------- ---------- --------- -----------
                0                       40                      80                      160                     0         40         80        160         0     40          80        160         0       40         80        160
  AG100         0.25                    0.125                   0.125                   0.125                   512       512        512       512         2     1           1         1           200     200        100       **50**
  AG100A        0.03                    0.03                    --                      --                      2         1          --        --          0.5   0.25        --        --          3.125   **0.39**   --        --
  AG100 ~tet~   1                       0.5                     **0.25**                **0.25**                \>2,048   \>2,048    2,048     2,048       64    **16**      **16**    **16**      512     512        512       512
                **\[PA*β*N\] (*μ*M)**   **\[PA*β*N\] (*μ*M)**   **\[PA*β*N\] (*μ*M)**   **\[PA*β*N\] (*μ*M)**                                                                                                                   
                0                       40                      80                      160                     0         40         80        160         0     40          80        160         0       40         80        160
  AG100         0.25                    **0.06**                **0.06**                **0.06**                512       **64**     **64**    **64**      2     2           1         **0.06**    200     100        100       100
  AG100A        0.03                    0.03                    --                      --                      2         **0.25**   --        --          0.5   **0.03**    --        --          3.125   3.125      --        --
  AG100~tet~    1                       **0.06**                **0.03**                **0.03**                \>2,048   **256**    **256**   **64**      64    **8**       **4**     **2**       512     256        **128**   **4**
                **\[CPZ\] (*μ*M)**      **\[CPZ\] (*μ*M)**      **\[CPZ\] (*μ*M)**      **\[CPZ\] (*μ*M)**                                                                                                                      
                0                       40                      80                      160                     0         40         80        160         0     40          80        160         0       40         80        160
  AG100         0.25                    0.125                   0.125                   **0.003**               512       512        512       **≤1**      2     1           **0.5**   **≤0.03**   200     100        **25**    **≤0.39**
  AG100A        0.03                    0.015                   --                      --                      2         2          --        --          0.5   **0.125**   --        --          3.125   **0.39**   --        --
  AG100 ~tet~   1                       0.5                     0.5                     **0.25**                \>2,048   \>2,048    2,048     **1,024**   64    32          32        **16**      512     256        **128**   **128**

**Notes.**

*E. coli* AG100---wild-type.

*E. coli* AG100A---AG100 with the AcrAB-TolC efflux pump inactivated.

*E. coli* AG100~tet~---AG100 with efflux pump overexpression

CPZchlorpromazineEtBrethidium bromideOFXofloxacinOXAoxacillinPA βNphe-arg- β-naphthylamideTETtetracycline--AG100A does not grow at concentration above 40  μM of PQQ4R

The presence of PAβN significantly reduced the MICs of OXA and TET on the three strains. PAβN reduced the MIC of TET and OXA on the pump-deficient strain by 16-fold and 4-fold, respectively; however, it showed no effect on OFX and EtBr MICs. Conversely, the exposure to PAβN produced a 128-fold decreased in the MIC of EtBr against the AcrAB-overexpressing strain, while no change was observed in the MIC of the wild-type strain. The inability of PAβN to reduce the MIC of EtBr in wild-type strains has already been described for *E. coli* and *P. aeruginosa* ([@ref-17]; [@ref-14]). This result indicates that PAβN is acting as a pump competitor and not as an efflux inhibitor like PQQ4R and CPZ. The activity of CPZ against the pump-deficient strain was similar to that of PQQ4R, with the exception that CPZ reduced the MIC of TET by 4-fold. CPZ significantly reduced the MICs of OFX, OXA, TET and EtBr on the wild-type and the AcrAB-overexpressing strain.

Efflux inhibitory activity of PQQ4R
-----------------------------------

The MIC results give an indirect measure of the potential efflux activity of the strains and the effect of the inhibitors on this activity. The ability of PQQ4R to inhibit *E. coli* efflux systems was confirmed by real-time fluorometry using EtBr, a broad efflux pump substrate ([@ref-40]; [@ref-42]). Initially, it was determined the equilibrium concentration at which the influx of EtBr equals its efflux. The accumulation of EtBr started at concentrations above 1 µg/ml for AG100, 0.25 µg/ml for AG100A, and 2 µg/ml for AG100~tet~ ([Fig. S1](#supp-1){ref-type="supplementary-material"}). Using these concentrations, we evaluated the ability of PQQ4R, at sub-inhibitory concentrations (\<1/8 MIC), to promote the intracellular accumulation of EtBr ([Fig. 1](#fig-1){ref-type="fig"}) and calculated the RFFs ([Table 3](#table-3){ref-type="table"}). The RFF value is a measure of how effective the compound is on the inhibition of the EtBr efflux (at a given concentration) by comparison of the final fluorescence at the last time point (60 min) of the treated cells with the cells treated only with EtBr. An index of activity above zero indicated that the cells accumulate more EtBr under the condition used than those of the control (non-treated cells taken as 0). In case of negative RFF values, these indicated that the treated cells accumulated less EtBr than those of the control condition. Values above 1 in the presence of the efflux inhibitors were considered enhanced accumulation of EtBr inside the cells. CPZ and PAβN were included at the same concentrations for a direct comparison of their inhibitory potencies.

![Effect of PQQ4R, CPZ, and PAβN on the accumulation of ethidium bromide by *E. coli*.\
(A) AG100; (B) AG100A; and (C) AG100~tet~. The equilibrium concentration of ethidium bromide was 1 μg/ml for AG100, 0.25 μg/ml for AG100A, and 2 μg/ml for AG100~tet~. Assays were performed at 37 °C in the absence of glucose. The inhibitors were used at 80 μM for AG100 and AG100~tet~, and 20 μM for AG100A. EtBr, ethidium bromide; CPZ, chlorpromazine; PAβN, phenyl-arginine- β-naphthylamide.](peerj-05-3168-g001){#fig-1}
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###### Relative final fluorescence values (RFF) based on the accumulation of EtBr for the *E. coli* strains in the presence of the efflux inhibitors.

![](peerj-05-3168-g011)

  AG100[^a^](#table-3fn1){ref-type="fn"}   AG100A[^b^](#table-3fn2){ref-type="fn"}   AG100~tet~[^c^](#table-3fn3){ref-type="fn"}                                
  ---------------------------------------- ----------------------------------------- --------------------------------------------- -------------------- ------- --------------------
  PQQ4R                                    **13.1 ± 0.04\*\*\***                     PQQ4R                                         **1.5 ± 0.1\*\***    PQQ4R   **5.2 ±0.9\*\*\***
  CPZ                                      **8.1 ± 1.1\*\*\***                       CPZ                                           **2.0 ± 0.04\*\***   CPZ     **7.9 ±0.4\*\*\***
  PAβN                                     0.7 ± 1.2\*                               PAβN                                          0.1 ± 0.1            PAβN    **1.3 ± 0.3\*\***

**Notes.**

*E. coli* AG100---wild-type.

*E. coli* AG100A---AG100 with the AcrAB-TolC efflux pump inactivated.

*E. coli* AG100~tet~---AG100 with efflux pump overexpression.

CPZ, chlorpromazine; EtBr, ethidium bromide; PAβN, phe-arg- β-naphthylamide; Accumulation of EtBr at 1 μg/ml (AG100), 0.25 μg/ml (AG100A) and 2 μg/ml (AG100~tet~) in the absence of glucose; Values in bold type (RFF ≥1) indicated enhanced accumulation of EtBr in presence of an efflux inhibitor. The results presented correspond to the average of three independent assays plus standard deviation (**±**SD). Results were considered significant when \**P* \< 0.05 and highly significant when \*\**P* \< 0.01 and \*\*\**P* \< 0.001; CPZ, chlorpromazine; PAβN, phe-arg- β-naphthylamide, EtBr, ethidium bromide.

At 80 µM, PQQ4R showed an RFF of 13.1 against the wild-type strain, indicating a strong ability to interfere with EtBr efflux compared to CPZ and PAβN, that showed RFF values of 8.1 and 0.7, respectively ([Fig. 1A](#fig-1){ref-type="fig"}; [Table 3](#table-3){ref-type="table"}). This means that PQQ4R promotes the higher accumulation levels of EtBr compared to CPZ followed by PAβN. In the AcrAB-deficient strain there was a small increase in the accumulation of EtBr in the presence of PQQ4R (RFF = 1.5) and CPZ (RFF = 2), whereas almost no effect was observed with PAβN (RFF = 0.1) ([Fig. 1B](#fig-1){ref-type="fig"}; [Table 3](#table-3){ref-type="table"}). These results showed once again that AcrAB is the main efflux system that pumps out EtBr in *E. coli*, but that other efflux pumps susceptible to PQQ4R and CPZ are pumping out EtBr as described before ([@ref-39]; [@ref-41]). For the AcrAB-overexpressing strain AG100~tet~ (AcrAB is 6--10 times overexpressed compared to the wild-type strain), the accumulation of EtBr in the presence of PQQ4R corresponded to a RFF of 5.2 ([Fig. 1C](#fig-1){ref-type="fig"}; [Table 3](#table-3){ref-type="table"}). The EtBr accumulation in this strain increased significantly when compared to AG100A, but, for the same molar concentration of inhibitor tested (80 µM), did not reach the same levels of inhibition observed for AG100, since the AcrAB system is 6--10 times more expressed in the AG100~tet~ strain compared with the AG100 ([@ref-40]; [@ref-42]). These results, obtained in a set of three isogenic *E. coli* that differ only by the absence/presence or expression level of the AcrAB system, indicated that PQQ4R promotes accumulation (i.e., interferes with the efflux) of EtBr in *E. coli* mainly thought the inhibition of the AcrAB efflux system. In the presence of CPZ and PAβN, the EtBr accumulation in the AG100~tet~ reaches similar levels (RFF 7.9 and 1.3, respectively) to those obtained for the wild-type strain (RFF 8.1 and 0.7, respectively), being less effective in the inhibition of efflux activity than PQQ4R.

To confirm the results obtained above on the accumulation of EtBr promoted by the inhibitors, we performed efflux assays for each strain. Each strain was subject to conditions that promote significant EtBr accumulation over a period of 60 min at room temperature: in the absence of glucose and presence of PQQ4R, CPZ or PAβN. After the maximum accumulation has been reached, EtBr and the efflux inhibitors were washed-out and the cells were subsequently re-suspended in new buffer with and without glucose and the inhibitor. As showed in [Fig. 2](#fig-2){ref-type="fig"}, the efflux take place readily in presence of glucose at 37 °C, an activity that is inhibited in the presence of PQQ4R and CPZ and to a lesser extent with PAβN. These results confirmed that PQQ4R, CPZ, and PAβN inhibit the efflux of EtBr and this inhibitory effect is transient when the cells are washed-out of the inhibitor and an energy source is given to promote active efflux reenergizing the cells ([Fig. 2](#fig-2){ref-type="fig"}).

![Effect of PQQ4R, CPZ, and PAβN on the efflux of EtBr by the *E. coli* strains.\
(A) AG100; (B) AG100A; and (C) AG100~tet~. The assays were performed at 37 °C in the presence and absence of glucose. The concentrations of PQQ4R, CPZ and PAβN were 80 μM for AG100 and AG100~tet~, and 20  μM for AG100A. EtBr, ethidium bromide; CPZ, chlorpromazine; PAβN, phenyl-arginine-β-naphthylamide.](peerj-05-3168-g002){#fig-2}

![Membrane depolarization (A) and permeabilization (B).\
The relative red/green ratio of *E. coli* using DIOC~2~ (3) stained cells after 30 min of exposure to PQQ4R from 80 μM to 640 μM. Green fluorescence corresponds to the depolarized cells; red fluorescence corresponds to the polarized cells. The changes in the fluorescence were measured at an excitation wavelength of 485/20 nm and 528/20 (emission) for green and 590/35 (emission) for red; (B) Membrane permeability measured with Baclight Live/Dead assay upon exposure to PQQ4R. Green fluorescence corresponds to the cells with intact membranes; red fluorescence corresponds to cells with permeabilized membranes cells. The data was normalized against the drug-free control. CCCP was used as positive control, at 156  μM (half MIC), since it eradicates the proton gradient, eliminating membrane potential. The results presented correspond to the average of two independent assays plus standard deviation (±SD). Results were considered significant when ^∗^*P* \< 0.05 and highly significant when ^∗∗^*P* \< 0.01 and ^∗∗∗^*P* \< 0.001.](peerj-05-3168-g003){#fig-3}

Membrane depolarization and cell viability
------------------------------------------

To test the hypothesis that the interference with the bacterial energy metabolism is the cause of the efflux inhibition by PQQ4R, the effect of this compound on the bacterial membrane potential was evaluated using the BacLight Bacterial Membrane Potential Kit. Thirteen minutes after adding PQQ4R at any of the concentrations tested, the percentage of depolarized cells was over 85% ([Fig. 3A](#fig-3){ref-type="fig"}). The protonophore CCCP was used as depolarization control and, as expected, the membrane potential collapsed when the cells were incubated for the same time with CCCP (over 95%). These results showed that PQQ4R depolarizes *E. coli* membranes by interfering with the gradient of protons through the cell membrane. Then, to evaluate if the depolarization of the cells, promoted by PQQ4R, results on a transient effect on cells with an intact membrane or alters the membrane integrity, the Live/Dead BacLight Bacterial Viability Kit was used. This assay uses the fluorescent stain SYTO 9 that penetrates in all bacterial membranes and stains the cells in green, and propidium iodide that penetrates only in the cells with permeabilized membranes. The combination of the two stains produces red fluorescent cells and these latter ones are considered dead by cell damage. The integrity of *E. coli* membranes was evaluated, by fluorometry, after exposure to PQQ4R at sub-inhibitory (1/4 and 1/2 MIC) and bactericidal concentrations (MIC), during 1 h. The results showed that at half MIC, PQQ4R caused cell damage, reducing the membrane integrity by 28% ([Fig. 3B](#fig-3){ref-type="fig"}). This increased membrane permeability was accompanied by a reduction in the bacterial viability of approx. 1 log ([Fig. 4](#fig-4){ref-type="fig"}---see also kinetics of bacterial killing). Membrane integrity was then evaluated on the cells exposed to PQQ4R at 80 µM (≈1/8 MIC), the same concentration used in the real-time fluorometry accumulation and efflux assays, for 1 h and the results were assessed as described before. At 80 µM, PQQ4R did not alter the cell membrane integrity ([Fig. 3B](#fig-3){ref-type="fig"}). To evaluate if the EtBr accumulation observed in presence of CPZ and PAβN was due to membrane permeability we tested both compounds also at 80 µM. The results showed that the membrane permeability increased by 18% and 14% with CPZ and PAβN, respectively. Membrane depolarization occurs in presence of CPZ at 80 µM similarly to that caused by PQQ4R, and PAβN induced 14% membrane depolarization at 80 µM. Overall, these results showed that PQQ4R causes transient membrane depolarization without affecting membrane integrity or cell viability at low concentrations (80 µM - 1/8 MIC- cell viability at this concentration 14.34 log~10~ CFU/ml---[Fig. 4](#fig-4){ref-type="fig"}). In contrast, and as expected by the previous results, at bactericidal concentrations, PQQ4R acts as a membrane-destabilizing agent, which is also consistent with the cell death at this concentration ([Fig. 4](#fig-4){ref-type="fig"}). The gathering of these results points towards the depolarization of the cell membrane as the main mechanism for PQQ4R's transient efflux-inhibition activity.

![Effect for PQQ4R on survival of *E. coli.* AG100.\
The compound was added at concentrations from 0.5× MIC (320  μM) to 8× MIC (5,120 μM) to exponential growing *E. coli* and survival monitored during 24 h.](peerj-05-3168-g004){#fig-4}

PQQ4R effect on intracellular ATP levels
----------------------------------------

Destabilization of the membrane functions can impair the respiratory chain functions and consequently reduce the ATP levels. To evaluate whether the exposure to PQQ4R could have an effect on the intracellular ATP levels, *E. coli* AG100 was exposed to PQQ4R and the intracellular ATP levels measured during 24 h at either sub-inhibitory (320 µM --1/2 MIC) or bactericidal concentrations (640 µM---MIC) ([Fig. 5](#fig-5){ref-type="fig"}). The ATP levels remained constant during the first 3 h of exposure at both concentrations and at the same level of the drug-free control excluding the abrupt ATP depletion from being the direct cause of the efflux-inhibition previously seen with the EtBr accumulation and efflux assays, and supports a slow but steady ATP production impairment. After 4 h of exposure, the ATP levels of the drug-free control increased but the ATP levels of the drug-containing tubes remained practically constant after the addition of PQQ4R and until the end of the assay, with the exception of the cells exposed to half MIC. In this case, the ATP production increased after 24 h of exposure but was 80% less than that of the drug-free control.

![Effect of PQQ4R on *E. coli* ATP levels.\
*E. coli* AG100 was exposed to PQQ4R at half MIC and MIC/MCB during 24 h. The ATP levels were quantified using a luciferin-luciferase bioluminescence detection assay as described in 'Material and Methods'. The results presented correspond to the average of two independent assays plus standard deviation (±SD). Results were considered significant when ^∗^*P* \< 0.05 and highly significant when ^∗∗^*P* \< 0.01 and ^∗∗∗^*P* \< 0.001.](peerj-05-3168-g005){#fig-5}

Kinetics of PQQ4R bacterial killing
-----------------------------------

To characterize the killing effect of PQQ4R, we measured its bacterial killing activity against AG100 through time-kill studies ([Fig. 4](#fig-4){ref-type="fig"}). PQQ4R at half MIC had no effect on the viability of *E. coli* after 24 h of exposure. Exposure to PQQ4R reduced the viability of *E. coli* to zero after 3 h at the MIC (256 µg/ml--640 µM) while at 2× MIC PQQ4R reduced the viability to zero after 1 h of exposure. After 24 h of exposure, all cultures remained negative at these concentrations. These results showed that PQQ4R killing activity is rapid reaching 100% lethality at the MIC, a concentration that was also found to be bactericidal (minimal bactericidal concentration---MBC).

Spectrum of activity of PQQ4R
-----------------------------

The antimicrobial activity of PQQ4R was evaluated against other bacterial species to assess its antibacterial specificity: the Gram-negative bacteria *Acinetobacter baumannii*, *Salmonella enterica* serovar Enteritidis, *Klebsiella pneumoniae* and *Enterobacter aerogenes*, the Gram-positive *S. aureus*, and the acid-fast bacteria *Mycobacterium smegmatis*, *M. avium*, and *M. tuberculosis*. The results are depicted in [Table 4](#table-4){ref-type="table"} and showed that PQQ4R possessed moderate antibacterial activity towards Gram-positive (average MIC 50 µg/ml) and acid-fast bacteria (average MIC 32 µg/ml) and reduced antibacterial activity against Gram-negative bacteria (average MIC ≥128 µg/ml).

10.7717/peerj.3168/table-4

###### Antibacterial specificity of PQQ4R against a panel of selected bacterial species.

![](peerj-05-3168-g012)

  Species                                     **Strain**      **MIC (*μ*g/ml)**
  ------------------------------------------- --------------- -------------------
  *Enterobacter aerogenes*                    ATCC13048       \>256
  *Salmonella enterica* serovar Enteritidis   NCTC13349       256
  *Escherichia coli* K-12                     AG100           256
  *Acinetobacter baumannii*                   ATCC19606^T^    128
  *Klebsiella pneumoniae*                     FF4891          \>256
  *Staphylococcus aureus*                     ATCC25923       50
  *Mycobacterium smegmatis* mc^2^155          ATCC700084^T^   32
  *Mycobacterium avium*                       104             32
  *Mycobacterium tuberculosis* H37Rv          ATCC27294^T^    32

Cytotoxicity
------------

Finally, PQQ4R was evaluated for its toxicity against human monocyte-derived macrophages using CPZ and PAβN for comparison. After 72 h of exposure, the viability of the macrophages was assessed using the AlamarBlue method. The comparative activities, CC~90~, CC~50~ and CC~10~ values, are presented in [Table 5](#table-5){ref-type="table"}. The dose--response curves are shown in [Fig. 6](#fig-6){ref-type="fig"}. PQQ4R showed to be more toxic (CC~50~ 10.83 µM) when compared to CPZ (CC~50~ 22.24 µM) and PAβN (CC~50~1269 µM). Afterwards, the amount of LDH release was measured in the cultures supernatants ([Fig. 7](#fig-7){ref-type="fig"}). The LDH is an intracellular enzyme that is released in the culture media as a consequence of damaged cell membranes ([@ref-5]). The treatment with PQQ4R at 0.625 µM--2.5 µM caused 1%--4.6% increase in LDH release compared with the non-treated cells; at 5 µM LDH release increases by 52.45% and to 72%--78% at higher concentrations. Comparatively, CPZ increases LDH release from 0.95% at 1.25 µM to 24% at 20 µM. At concentrations above, the amount of LDH detected in the culture supernatant was above 95%. Concerning PAβN, the amount of LDH detected varied from 1.08% to 8% at concentrations from 10 µM to 640 µM. At concentrations above, PAβN caused 66%--68% LDH release. The results obtained with the LDH method corroborated the results obtained with the AlamarBlue method.

10.7717/peerj.3168/table-5

###### Cytotoxic concentrations (CC) of PQQ4R, PA*β*N, and CPZ against human monocyte-derived macrophages after three days of exposure.

![](peerj-05-3168-g013)

          Cytotoxic concentrations (*μ*M)           
  ------- --------------------------------- ------- --------
  PQQ4R   12.73                             10.83   9.21
  CPZ     37.01                             22.24   13.36
  PAβN    3596.86                           1269    447.71

**Notes.**

CPZchlorpromazinePAβNphe-arg-β-naphthylamide

![Dose response curves showing the effect of PQQ4R, CPZ and PA*β*N against human-monocyte derived macrophages.\
The cells were treated with different concentrations of (A) PQQ4R, (B) CPZ, and (C) PAβN for 3 days; AlamarBlue was then added and cells were further incubated overnight at 37 °C, 5% CO~2~. The fluorescence was measured Synergy HT multi-mode microplate reader. CPZ, chlorpromazine; PAβN, phenyl-arginine-β-naphthylamide.](peerj-05-3168-g006){#fig-6}

![Effect of PQQ4R, CPZ and PA*β*N on LDH release from human monocyte-derived macrophages.\
The cells were exposed to each compound during 3 days at 37 °C, 5% CO~2~. The results presented correspond to the average of at least two independent assays plus standard deviation (±SD). Results were considered significant when ^∗^*P* \< 0.05 and highly significant when ^∗∗^*P* \< 0.01 and ^∗∗∗^*P* \< 0.001.](peerj-05-3168-g007){#fig-7}

Discussion
==========

To detail the biological activity on the 2-phenylquinoline efflux inhibitor PQQ4R against *E. coli*, we investigated first the synergistic activity of PQQ4R in combination with antibiotics that are known substrates of the AcrAB efflux pump. The results showed that PQQ4R acts synergistically, in a concentration dependent manner, with the antibiotics TET and OFX. When compared to CPZ and PAβN, PQQ4R is less potent in its synergistic activity at equivalent molarities. Next, we explored the effect of PQQ4R on the real-time active efflux of the AcrAB efflux substrate EtBr. PQQ4R, CPZ, and PAβN clearly inhibited the efflux of EtBr in a transient manner at sub-inhibitory concentrations (1/8 MIC or less), as shown by the reactivation of active efflux when the cells are released from the inhibitor and reenergized by glucose. As expected, the re-energization effect was more significant with CPZ (known to inhibit AcrAB-mediated EtBr efflux by energy depletion) ([@ref-39]) compared with PAβN, an AcrAB substrate competitor partially affecting membrane integrity ([@ref-21]). PQQ4R clearly demonstrated a real-time inhibitory effect on efflux similar to CPZ.

In terms of antimicrobial properties, PQQ4R demonstrated a rapid bactericidal activity against *E. coli* with the complete loss of viable cells after only 1 h incubation at 2× MIC and after 4 h at its MIC. This result is consistent with our hypothesis of an alternative mode of action in which at low concentrations PQQ4R inhibit *E. coli* efflux systems and near the MBC it interact directly with *E. coli* membranes. Our results showed that PQQ4R mechanism of action involves the loss of membrane integrity after 1 h of exposure. PQQ4R disrupts both inner and outer membrane, as the uptake of the membrane-impermeant fluorescent dye propidium iodide requires the damage of both to enter in the cytoplasm, to bind to the DNA and fluoresce. Recently, it was showed that PAβN also permeabilizes the *E. coli* outer membrane ([@ref-21]) and both outer and inner membranes of *P. aeruginosa* ([@ref-15]).

The loss of the membrane integrity is closely related with the loss of the cell capacity to synthesize ATP, decreased protein synthesis and to inhibit respiration ([@ref-4]). Our data showed a moderate increase in the ATP levels after the addition of PQQ4R at sub-inhibitory concentrations (half MIC), associated with a decrease in the membrane permeability. At bactericidal concentrations (MIC), the ATP levels decreased and were accompanied by an increase in the membrane permeability. To further support these results, and based upon the fact that the RND efflux pumps act using the electrochemical gradient generated by the PMF ([@ref-1]), we assessed whether treatment with PQQ4R could have a direct effect on membrane depolarization. Our results showed that PQQ4R causes a significant, but non-lethal, inner membrane depolarization at sub-inhibitory concentrations. At bactericidal concentrations, the membrane depolarization is accompanied by an impaired membrane integrity and ATP production, with cell death. The sequence of events describing PQQ4R mechanism of action is depicted in [Fig. 8](#fig-8){ref-type="fig"}. Briefly, PQQ4R at low concentrations inhibit *E. coli* efflux systems by interfering with the energy necessary to maintain the pumps working, i.e., PQQ4R is an energetic inhibitor like CPZ and inhibits the efflux activity through the transient dissipation of the membrane potential without affecting the membrane permeability. Also similar to CPZ and PAβN, at higher concentrations PQQ4R permeabilizes *E. coli* membranes causing irreversible cell damage leading to the cell death. Of note, despite several attempts, we could not obtain *E. coli* mutants to PQQ4R. This result showed that PQQ4R has an off-target effect and corroborates our findings that points to membrane disruption as the primary mechanism of action of this molecule.

![Sequence of events describing PQQ4R mechanism of action.\
PQQ4R mode of action involves efflux pump inhibition, membrane permeabilization, disruption of membrane potential, and ATP depletion. PQQ4R act as efflux inhibitor at low concentrations (80 μM) by interference with energy required for efflux due to its interference with inner membrane potential. At sub-inhibitory concentrations (160 μM and 320 μM), PQQ4R destabilizes *E. coli* membrane functions in a non-permanent manner as suggested by the reduction of ATP levels, depolarization of membrane potential and increased membrane permeabilization; at the MBC (640 μM), membrane permeabilization increases and ATP is lost.](peerj-05-3168-g008){#fig-8}

Regrettably, PQQ4R revealed to be relatively toxic to the human macrophage, with a toxicity level comparable to that of CPZ, an antipsychotic already used in clinical practice and previously shown to have activity against intracellular *M. tuberculosis* at non-toxic clinical concentrations due to its accumulation inside the phagolysosomal macrophage compartments ([@ref-19]). In a recent study, we showed that PQQ4R, when used at non-toxic concentrations, is also able to potentiate clarithromycin activity against intracellular *M. avium* in a manner similar to CPZ ([@ref-18]). On the contrary, PAβN showed almost no toxicity against the human macrophages, however, PAβN and its derivatives proved to be nephrotoxic as result of their accumulation in lysosomes. This adversity has hampered the clinical development of PAβN ([@ref-43]). The intriguing activity of PQQ4R may be used as a starting point for the much-needed medicinal chemistry approaches to identify potent RND efflux pumps inhibitors endowed of a suitable safety profile.

In conclusion, PQQ4R is an excellent hit candidate to be studied in depth to find new RND efflux pumps inhibitors of Gram-negative bacteria that act by interfering with the PMF. It shows a broad usefulness as efflux pump inhibitor and, due to its membrane permeabilizing properties, can be used in combination therapies to assist other molecules to enter the bacterial cell ([@ref-15]; [@ref-13]). Moreover, this compound complies with the conditions of [@ref-10]'s et al., ([@ref-10]) hypothesis that presented an alternative approach to tackle pathogens by using chemical combinations targeting the PMF. The authors showed that combinations between dissipaters of membrane potential with dissipaters of the transmembrane proton gradient are highly synergistic against methicillin-resistant *S. aureus*. This combination will allow reducing each compound individual dose and consequently, their toxicity ([@ref-10]). Since drug resistance mediated by efflux pumps depend largely on the PMF, dissipaters of the PMF as PQQ4R could be regarded as putative adjuvants of the conventional therapy against bacterial pathogens. Nevertheless, due to the similarities between the bacterial and the mitochondrial electron transport chain, the effect of PQQ4R on the latter will need to be evaluated in the future. Medicinal chemistry studies can now help to improve PQQ4R scaffold to potentiate its permeabilizing and efflux inhibitory properties and reduce its toxicity towards human cells, contributing for the development of new drugs with potential for the clinical usage as adjuvants of the therapy against drug resistant bacterial pathogens.
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###### Determination of the equilibrium concentration between influx and efflux of ethidium bromide by *E. coli* (A) AG100, (B) AG100A and (C) AG100 ~tet~ The equilibrium concentration of ethidium bromide was 1 μg/ml for AG100, 0.25 μg/ml for AG100A, and 2 μg/ml for AG100 ~tet~. Etbr, ethidium bromide.
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